var data={"title":"Ciprofloxacin (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ciprofloxacin (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/231814?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ciprofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ciprofloxacin (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=ciprofloxacin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ciprofloxacin (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611220\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious adverse reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including: tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones have been associated with serious adverse reactions, reserve ciprofloxacin for use in patients who have no alternative treatment options for the following indications: acute exacerbation of chronic bronchitis, acute sinusitis, and acute uncomplicated cystitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exacerbation of myasthenia gravis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid ciprofloxacin in patients with known history of myasthenia gravis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611233\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cipro;</li>\n      <li>Cipro in D5W;</li>\n      <li>Cipro XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611234\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cipro;</li>\n      <li>Cipro XL;</li>\n      <li>Ciprofloxacin Injection;</li>\n      <li>Ciprofloxacin Injection USP;</li>\n      <li>Ciprofloxacin Intravenous Infusion</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9660646\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Fluoroquinolone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611424\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Extended-release tablets and immediate-release formulations are not interchangeable. Unless otherwise specified, oral dosing reflects the use of immediate-release formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anthrax:</b>\n      <b> Note:</b> Consult public health officials for event-specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalational exposure (postexposure prophylaxis):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 500 mg every 12 hours for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 12 hours for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutaneous (without systemic involvement), empiric therapy (off-label use):</i> Oral: 500 mg every 12 hours for 7 to 10 days after naturally acquired infection; 60 days following biological weapon-related event (Hendricks 2014).<b> Note</b>: Patients with cutaneous lesions of the head or neck or extensive edema should be treated for systemic involvement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic (meningitis excluded) (off-label use): </i>IV: 400 mg every 8 hours in combination with other appropriate agents for 2 weeks until clinically stable (Hendricks 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Meningitis (off-label use): </i>IV: 400 mg every 8 hours in combination with other appropriate agents for 2 to 3 weeks until clinically stable (Hendricks 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Following the course of IV combination therapy for systemic anthrax infection (including meningitis), patients exposed to aerosolized spores require oral monotherapy to complete a total antimicrobial course of 60 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wound infection, prophylaxis or treatment (animal and human bites; alternative agent) (off-label use) (IDSA [Stevens 2014]): Note:</b> Use in combination with an appropriate agent for anaerobes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 500 to 750 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration of therapy: 3 to 5 days for prophylaxis; duration of treatment for established infection varies based on patient-specific factors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cat scratch disease, lymphadenitis (non-disseminated; alternative agent) (off-label use): </b>Oral: 500 mg twice daily (Holley 1991). Additional data may be necessary to further define the role of ciprofloxacin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chancroid (alternative agent) (off-label use): </b>Oral: 500 mg twice daily for 3 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera (<i>Vibrio cholerae</i>) (off-label use; alternative agent)<i>:</i></b> Oral: 1 g as a single dose (IDSA [Guerrant 2001]; Khan 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic foot infections (off-label use) (IDSA [Lipsky 2012]; Weintrob 2017): Note:</b> When used as empiric therapy, must be used in combination with other appropriate agents.</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Moderate: Oral: 500 mg every 12 hours (750 mg every 12 hours if <i>Pseudomonas</i> <i>aeruginosa</i> is suspected)</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Moderate to severe: IV: 400 mg every 12 hours (400 mg every 8 hours if <i>P. aeruginosa</i> is suspected)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis due to HACEK organisms (alternative agent) (off-label use) (AHA [Baddour 2015]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 500 mg every 12 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 12 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Granuloma inguinale (Donovanosis) (alternative agent) (off-label use):</b> Oral: 750 mg twice daily for at least 3 weeks (and until lesions have healed) (CDC [Workowski 2015]). <b>Note:</b> If symptoms do not improve within the first few days of therapy, another agent (eg, aminoglycoside) can be added (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic cell transplant (HCT) antibacterial prophylaxis (off-label use): </b>Oral: 500 mg twice daily; begin at the time of stem cell infusion and continue until recovery of neutropenia or until initiation of empiric antibiotic therapy for febrile neutropenia (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections </b>\n      <b>(including perforated appendix, appendiceal abscess, acute diverticulitis, acute cholecystitis), community-acquired: </b>\n      <b>Note:</b> For empiric therapy, use in combination with metronidazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration of therapy: Duration depends on whether source of infection has been controlled. Guidelines recommend treatment duration of 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis, bacterial (community-acquired or health care-associated; alternative agent) (off-label use):</b> IV: 400 mg every 8 to 12 hours; for empiric therapy, must be used in combination with other appropriate agents (IDSA [Tunkel 2004, 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal meningitis prophylaxis (off-label use):</b> Oral: 500 mg as a single dose (CDC 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neutropenia (chemotherapy-induced), antibacterial prophylaxis in high-risk patients anticipated to have an ANC &le;100 cells/mm<sup>3</sup> for &gt;7 days</b> <b>(off-label use):</b> Oral: 500 mg twice daily (IDSA [Freifeld 2011]; Wingard 2017); some clinicians will provide antibacterial prophylaxis if ANC is anticipated to be &lt;500 cells/mm<sup>3</sup> for &gt;7 days (Wingard 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neutropenic fever, low-risk cancer patients (empiric) (off-label use):</b> Oral: 750 mg every 12 hours until afebrile and neutropenia has resolved; use in combination with amoxicillin and clavulanate.<b> Note</b>: Avoid in patients who have received fluoroquinolone prophylaxis (ASCO [Flowers 2013]; IDSA [Freifeld 2011]; Kern 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 12 hours; when treating <i>P. aeruginosa</i>, 400 mg every 8 hours (Calhoun 2005; IDSA [Berbari 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 500 to 750 mg every 12 hours; when treating <i>P. aeruginosa</i>, 750 mg every 12 hours (Calhoun 2005; IDSA [Berbari 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic suppression in presence of retained infected orthopedic hardware: 250 to 500 mg every 12 hours (IDSA [Osmon 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritoneal dialysis catheter, exit site or tunnel infection (off-label use):</b> Oral: 250 mg twice daily. When used for empiric therapy, must be used in combination with other appropriate agents (ISPD [Szeto 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritonitis, spontaneous bacterial (prevention), high risk patients (eg, hospitalized patients with Child-Pugh class B or C cirrhosis and active GI bleeding) (alternative agent) (off-label use) (Runyon 2017):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 500 mg every 12 hours for total duration of 7 days (oral and IV)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (alternative for nonfunctional GI tract): 400 mg every 12 hours for total duration of 7 days (oral and IV)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Long-term secondary SBP prophylaxis:</i> Oral: 500 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague (<i>Yersinia pestis</i>) infection (alternative agent) (CDC [plague] 2015): Note: </b>Consult public health officials for event-specific recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Postexposure prophylaxis:</i> Oral: 500 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment: <b>Note:</b> Duration of therapy is </i>\n      <i>10 to 14 days </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 500 to 750 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired, as a component of empiric therapy for <i>P. aeruginosa</i> coverage (hospitalized patient) (off-label use) (File 2017a; IDSA/ATS [Mandell 2007]): Note:</b> For empiric therapy, must be used in combination with other appropriate agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 8 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 750 mg every 12 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, hospital-acquired (nosocomial) including ventilator-associated, as a component of empiric therapy for <i>P. aeruginosa</i> coverage (File 2017b; IDSA [Kalil 2016]): Note:</b> For empiric therapy, must be used in combination with other appropriate agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 8 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 750 mg every 12 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostatitis (acute, bacterial) (off-label use): Note: </b>When used for empiric therapy, must be used in combination with other appropriate agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 500 mg every 12 hours (Meyrier 2017a)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 12 hours (Meyrier 2017a)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration of therapy: 6 weeks (Meyrier 2017a; Yoon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostatitis (chronic, bacterial)</b> <b>(Meyrier 2017b)<b>:</b></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 500 mg every 12 hours for &ge;6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 12 hours for &ge;6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection (off-label use): Note: </b>Alternative agent for certain pathogens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gram-negative bacilli (IDSA [Osmon 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 750 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Staphylococci: Oral: 750 mg twice daily (Zimmerli 1998). <b>Note:</b> For use in combination with rifampin, following pathogen-specific IV therapy in patients undergoing 1-stage exchanges or debridement with retention of prosthesis (IDSA [Osmon 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic suppressive therapy (for P. aeruginosa): </i>Oral: 250 to 500 mg twice daily (IDSA [Osmon 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Salmonella</i> species, GI infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nontyphoidal, severe (non-bacteremic) illness or any severity in patients at high risk for invasive disease:</i> Oral: 500 mg twice daily for 3 to 7 days. <b>Note:</b> Immunosuppressed patients require longer duration of treatment (eg, weeks to months) (Hohmann 2017; IDSA [Guerrant 2001]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Typhoid fever (Salmonella typhi and paratyphi):</i> Severe disease or mild to moderate infection in patients at high-risk of developing invasive disease (Ryan 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 500 mg every 12 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 12 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic arthritis (without prosthetic material; alternative agent): Note:</b> Use in combination with an aminoglycoside for initial treatment if <i>P. aeruginosa</i> suspected (Goldenberg 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 500 to 750 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Shigella</i> GI infection (off-label dose):</b> Oral: 500 mg twice daily or 750 mg once daily for 3 days; the duration should be extended to 5 to 7 days for those with <i>S. dysenteriae</i> type 1 infection or HIV coinfection (Agha 2017; IDSA [Guerrant 2001]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (preoperative) prophylaxis (alternative agent) (off-label use): Note:</b> Use in combination with other appropriate agents may be warranted (procedure-dependent). IV: 400 mg within 120 minutes prior to surgical incision (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infection (intestinal or GU tract, perineum, or axilla) (off-label use) (IDSA [Stevens 2014]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 750 mg every 12 hours, in combination with metronidazole</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 400 mg every 12 hours, in combination with metronidazole</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler&rsquo;s diarrhea, uncomplicated (empiric therapy) (off-label dose): </b>Oral: 500 mg twice daily for 3 days <b>or</b> 750 mg as a single dose (ACG [Riddle 2016]); Riddle 2017). If symptoms not resolved after 24 hours following single-dose therapy, continue with 500 mg twice daily for 2 more days. The 3-day therapy course is recommended in patients with fever or dysentery; enteric infection due to <i>Shigella dysenteriae</i> is an exception as a 5-day treatment duration appears to be superior to single-dose or 3-day regimens (ACG [Riddle 2016]). Adjunctive loperamide may be considered in patients receiving antibiotic therapy, in particular for immunocompetent adults with acute watery diarrhea (ACG [Riddle 2016]; IDSA [Shane 2017]; Riddle 2017). <b>Note:</b> Fluoroquinolone resistance is increasing; azithromycin may be preferred, particularly in regions such as southeast Asia or India with a high prevalence of Campylobacter (ACG [Riddle 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tularemia (<i>Francisella tularensis</i>) (off-label use): </b>\n      <b>Note:</b> Consult public health officials for event-specific recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild disease or postexposure prophylaxis:</i> Oral: 500 or 750 mg twice daily (Bossi 2004; Dennis 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cystitis, acute uncomplicated:</i> <b>Note: </b>Use for uncomplicated urinary tract infections is discouraged due to significant <i>E. coli</i> resistance and safety issues; reserve for clinical situations where other appropriate treatment options cannot be used (Bidell 2016; IDSA [Gupta 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 250 mg every 12 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, extended release: 500 mg every 24 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cystitis, acute complicated </i>(Hooton 2017)<i>: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 250 mg every 12 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, extended release: 1,000 mg every 24 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pyelonephritis, uncomplicated (outpatient): </i>Oral: 500 mg every 12 hours for 7days (IDSA [Gupta 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pyelonephritis, complicated (inpatient)</i>: IV: 400 mg every 12 hours for a total of 7 to 14 days (Hooton 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611423\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ciprofloxacin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ciprofloxacin (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In pediatric patients, ciprofloxacin is not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for some situations [eg, anthrax, resistance (cystic fibrosis)] or in situations where the only alternative is parenteral therapy and ciprofloxacin offers an oral therapy option (Bradley 2011b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Extended release tablets and immediate release formulations are not interchangeable. Unless otherwise specified, oral dosing reflects the use of immediate release formulations.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Usual dosage range</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate infections: Oral: 10 mg/kg/dose twice daily (maximum dose: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infections:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 15 to 20 mg/kg/dose twice daily (maximum dose: 750 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 mg/kg/dose every 8 to 12 hours (maximum dose: 400 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anthrax:</b> Infants, Children, and Adolescents: <b>Note:</b> Consult public health officials for event-specific recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalational exposure (postexposure prophylaxis):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 15 mg/kg/dose every 12 hours for 60 days (maximum dose: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 mg/kg/dose every 12 hours for 60 days; do <b>not</b> exceed 400 mg/dose (800 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutaneous, treatment (without systemic involvement) (off-label use) (Bradley 2014):</i> Oral: 15 mg/kg/dose every 12 hours (maximum dose: 500 mg/dose). Duration: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related event.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic, treatment (including meningitis) (off-label use) (Bradley 2014):</i> IV: Initial: 10 mg/kg/dose every 8 hours (maximum dose: 400 mg/dose) as part of combination therapy; continue until clinical criteria for stability are met, then may switch to oral therapy (15 mg/kg/dose orally twice daily) to complete a 60-day course</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chancroid (off-label use):</b> Adolescents: Oral: 500 mg twice daily for 3 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, culture negative, empiric therapy (off-label use):</b> <b>Note:</b> Administer in combination with other antibiotics: Children and Adolescents (AHA [Baltimore 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 10 to 15 mg/kg/dose twice daily for 4 to 6 weeks; maximum dose: 750 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 to 15 mg/kg/dose twice daily for 4 to 6 weeks; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated (off-label use):</b> Infants, Children, and Adolescents: IV: 10 to 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal invasive disease prophylaxis, high-risk contacts (off-label use):</b> Infants, Children, and Adolescents: Oral: 20 mg/kg as a single dose; maximum dose: 500 mg/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Mycobacterium avium</i> complex, severe or disseminated disease, HIV-exposed/-infected (off-label use)</b>: Infants and Children: Oral: 10 to 15 mg/kg/dose twice daily in addition to other antibiotics; maximum dose: 750 mg/dose (HHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritoneal dialysis catheter, exit site or tunnel infection (off-label use): </b>Infants, Children, and Adolescents: Oral: 10 to 15 mg/kg/dose once daily (maximum dose: 500 mg/dose) (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 15 mg/kg/dose every 8 to 12 hours for 10 to 21 days; maximum: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 mg/kg/dose every 8 to 12 hours for 10 to 21 days; maximum: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing </i>(CDC [plague] 2015)<i>:</i> Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial treatment: IV: 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose; continue until 2 days after fever subsides, then may change to oral therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral step down to complete a 10 to 14 day course: Oral: 20 mg/kg/dose twice daily; maximum dose: 500 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Postexposure prophylaxis:</i> Oral: 20 mg/kg/dose twice daily for 7 days; maximum dose: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired (</b>\n      <b>\n        <i>H. influenzae</i>) (off-label use):</b> Infants &gt;3 months and Children: IV: 15 mg/kg/dose every 12 hours (IDSA/PIDS [Bradley 2011a])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (preoperative) prophylaxis (off-label use):</b> Children and Adolescents: IV: 10 mg/kg/dose within 120 minutes prior to surgical incision (maximum dose: 400 mg/dose) (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cystitis, acute uncomplicated: Adolescents &ge;18 years: Oral, extended release: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Complicated, including pyelonephritis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: Children and Adolescents &le;17 years: 10 to 20 mg/kg/dose every 12 hours for 10 to 21 days; maximum dose: 750 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, extended release: Adolescents &ge;18 years: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 6 to 10 mg/kg/dose every 8 hours for 10 to 21 days (maximum dose: 400 mg/dose)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611425\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611426\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral, immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 30 to 50 mL/minute: 250 to 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 5 to 29 mL/minute: 250 to 500 mg every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">ESRD on intermittent hemodialysis (IHD)/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 250 to 500 mg every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral, extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;30 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">ESRD on intermittent hemodialysis (IHD)/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 500 mg every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 5 to 29 mL/minute: 200 to 400 mg every 18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Alternate recommendations:</i> Oral (immediate release), IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10 to 50 mL/minute: Administer 50% to 75% of usual dose every 12 hours (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer 50% of usual dose every 12 hours (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Minimally dialyzable (&lt;10%): Oral: 250 to 500 mg every 24 hours <b>or</b> IV: 200 to 400 mg every 24 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CVVH/CVVHD/CVVHDF: IV: 200 to 400 mg every 12 to 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22902778\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling. Use with caution in severe impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611523\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro in D5W: 200 mg/100 mL (100 mL [DSC]) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/100 mL (100 mL); 400 mg/200 mL (200 mL); 200 mg/20 mL (20 mL [DSC]); 400 mg/40 mL (40 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro in D5W: 200 mg/100 mL (100 mL [DSC]); 400 mg/200 mL (200 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/100 mL (100 mL); 400 mg/200 mL (200 mL); 200 mg/20 mL (20 mL); 400 mg/40 mL (40 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro: 250 mg/5 mL (100 mL); 500 mg/5 mL (100 mL) [strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/5 mL (100 mL [DSC]); 500 mg/5 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 250 mg, 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as base and hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro XR: 500 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 1000 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611236\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611231\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cipro: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019537s087,020780s044lbl.pdf#page=41&amp;token=afrhIpcbZFX4oRFb2twpYUzxqF82YuMQVo5cVtn7YrDqZQhBQb6uvO53Nku5Gl+Xb8t6znCszLEWEK1lyMFX3ZfqlggGrjol4AhU6CJafm8jgn0rwd3G58A6UDEewfdY&amp;TOPIC_ID=9053\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019537s087,020780s044lbl.pdf#page=41</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611451\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May administer with most foods to minimize GI upset; avoid antacid use; maintain proper hydration and urine output. Avoid concomitant administration with dairy products (eg, milk, yogurt) or calcium-fortified juices alone, however, may be taken with meals that contain these products; separate administration of Cipro XR and calcium &gt;800 mg by at least 2 hours. Administer immediate release ciprofloxacin and Cipro XR at least 2 hours before or 6 hours after antacids or other products containing calcium, iron, or zinc. Separate oral administration from drugs which may impair absorption (see Drug Interactions).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension: Should not be administered through feeding tubes (suspension is oil-based and adheres to the feeding tube). Shake vigorously before use for ~15 seconds; administer using the co-packaged graduated teaspoon. Do not chew the microcapsules in the suspension; swallow whole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasogastric/orogastric tube: Crush immediate-release tablet and mix with water. Flush feeding tube before and after administration. Hold tube feedings at least 1 hour before and 2 hours after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, extended release: Do not crush, split, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer by slow IV infusion over 60 minutes into a large vein (reduces risk of venous irritation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611256\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents: Treatment of complicated urinary tract infections and pyelonephritis due to <i>E. coli</i>. <b>Note:</b> Although effective, ciprofloxacin is not the drug of first choice in children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, Adolescents, and Adults: Prophylaxis to reduce incidence or progression of disease following inhalation exposure to <i>Bacillus anthracis</i>; prophylaxis and treatment of plague (<i>Yersinia pestis</i>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Treatment of the following infections when caused by susceptible bacteria: Urinary tract infections; acute uncomplicated cystitis in females, chronic bacterial prostatitis, bone and joint infections, complicated intra-abdominal infections (in combination with metronidazole), infectious diarrhea, typhoid fever (<i>Salmonella typhi),</i> hospital-acquired (nosocomial) pneumonia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects), reserve ciprofloxacin for use in patients who have no alternative treatment options for acute uncomplicated cystitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475322\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Anthrax; Bite wound infection (animal and human bites); Cat scratch disease, lymphadenitis (non-disseminated); Chancroid; Cholera (Vibrio cholerae); Diabetic foot infections; Endocarditis, treatment (adults); Endocarditis, treatment (children/adolescents); Granuloma inguinale (Donovanosis); Hematopoietic cell transplant antibacterial prophylaxis; Meningitis, bacterial; Meningococcal disease (prevention and control); Mycobacterium avium complex (MAC), severe or disseminated disease, HIV-exposed/-infected (children); Neutropenia (chemotherapy-induced), antibacterial prophylaxis; Neutropenic fever, low-risk cancer patients (empiric); Peritoneal dialysis catheter-related infections; Peritonitis, spontaneous bacterial (prevention); Pneumonia, community-acquired; Prostatitis, acute bacterial; Prosthetic joint infection; Surgical prophylaxis; Surgical site infection; Tularemia (adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3198418\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ciprofloxacin may be confused with cephalexin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro may be confused with Ceftin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611304\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Neurological signs and symptoms (children 2%; includes dizziness, insomnia, nervousness, somnolence), headache (IV administration), restlessness (IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (children 2%, adults 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (children 5%; adults 2%), vomiting (children 5%; adults 1%), abdominal pain (children 3%; adults &lt;1%), dyspepsia (children 3%; adults &lt;1%), nausea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum AST (adults 1%), increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reactions (IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Rhinitis (children 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (children 2%; adults &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, acute generalized exanthematous pustulosis, acute gout attack, acute renal failure, ageusia, agitation, agranulocytosis, albuminuria, anaphylactic shock, anaphylaxis, anemia, angina pectoris, angioedema, anorexia, anosmia, anxiety, arthralgia, ataxia, atrial flutter, bone marrow depression (life-threatening), bronchospasm, candidiasis, candiduria, cardiorespiratory arrest, casts in urine, cerebral thrombosis, chills, cholestatic jaundice, chromatopsia, <i>Clostridium difficile</i>-associated diarrhea, confusion, constipation, crystalluria (particularly in alkaline urine), decreased hematocrit, decreased hemoglobin, decreased prothrombin time, delirium, depersonalization, depression (including self-injurious behavior), dizziness, drowsiness, dyspepsia (adults), dysphagia, dysphasia, dyspnea, edema, eosinophilia, erythema multiforme, erythema nodosum, exacerbation of myasthenia gravis, exfoliative dermatitis, fixed drug eruption, flatulence, gastrointestinal hemorrhage, hallucination, headache (oral), hematuria, hemolytic anemia, hepatic failure, hepatic necrosis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperesthesia, hyperglycemia, hyperpigmentation, hypersensitivity reaction, hypertension, hypertonia, hypoglycemia, hypotension, increased blood urea nitrogen, increased creatine phosphokinase, increased INR (in patients treated with vitamin K antagonists), increased intracranial pressure, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum bilirubin, increased serum cholesterol, increased serum creatinine, increased serum glucose, increased serum lipase, increased serum triglycerides, increased uric acid, insomnia, interstitial nephritis, intestinal perforation, irritability, jaundice, laryngeal edema, lethargy, lymphadenopathy, malaise, manic behavior, mastalgia, methemoglobinemia, migraine, myalgia, myocardial infarction, myoclonus, nephritis, nephrolithiasis, nightmares, nystagmus, orthostatic hypotension, palpitations, pancreatitis, pancytopenia (life-threatening), paranoia, paresthesia, peripheral neuropathy, petechia, phobia, phototoxicity, pneumonitis, polyneuropathy, prolonged prothrombin time (in patients treated with vitamin K antagonists), pseudotumor cerebri, pulmonary edema, rupture of tendon, seizure (including grand mal), serum sickness-like reaction, skin photosensitivity, status epilepticus, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, syncope, tachycardia, tendonitis, thrombocythemia, thrombocytopenia, thrombophlebitis, tinnitus, torsades de pointes, toxic epidermal necrolysis, toxic psychosis, tremor, twitching, unresponsive to stimuli, urethral bleeding, vaginitis, vasculitis, ventricular arrhythmia, ventricular ectopy, visual disturbance, vulvovaginal candidiasis, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611301\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ciprofloxacin, any component of the formulation, or other quinolones; concurrent administration of tizanidine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Concurrent administration of agomelatine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611302\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Altered cardiac conduction: Fluoroquinolones may prolong QT<sub>c</sub> interval; avoid use in patients with a history of or at risk for QT<sub>c</sub> prolongation, torsade de pointes, uncorrected hypokalemia, hypomagnesemia, cardiac disease (heart failure, myocardial infarction, bradycardia) or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Crystalluria: Rarely, crystalluria has occurred; urine alkalinity may increase the risk. Ensure adequate hydration during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as a systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity:  Hepatocellular, cholestatic, or mixed liver injury has been reported, including hepatic necrosis, life-threatening hepatic events, and fatalities. Acute liver injury can be rapid onset (range: 1-39 days), often associated with hypersensitivity. Most fatalities occurred in patients &gt;55 years of age. Discontinue immediately if signs/symptoms of hepatitis (abdominal tenderness, dark urine, jaundice, pruritus) occur. Additionally, temporary increases in transaminases or alkaline phosphatase, or cholestatic jaundice may occur (highest risk in patients with previous liver damage).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatitis, jaundice, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity/phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions which may appear as exaggerated sunburn reactions. Discontinue use if phototoxicity occurs. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Serious adverse reactions:<b>[US Boxed Warning]: Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ciprofloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions.</b> Patients of any age or without preexisting risk factors have experienced these reactions; may occur within hours to weeks after initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects including seizures, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis; may also cause nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or actions. May occur following the first dose; discontinue immediately and avoid further use of fluoroquinolones in patients who experience these reactions. Use with caution in patients with known or suspected CNS disorder, or risk factors that may predispose to seizures or lower the seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Peripheral neuropathy: Fluoroquinolones have been associated with an increased risk of peripheral neuropathy; may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur. Avoid use in patients who have previously experienced peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Tendinitis/tendon rupture: Fluoroquinolones have been associated with an increased risk of tendonitis and tendon rupture in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients &gt;60 years of age, but has also occurred in patients without these risk factors. Rupture of the Achilles tendon has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within hours or days of initiation, and up to several months after discontinuation of therapy. Strenuous physical activity, renal failure, and previous tendon disorders may be independent risk factor for tendon rupture. Discontinue at first sign of tendon pain, swelling, inflammation or rupture. Avoid use in patients with a history of tendon disorders or who have experienced tendinitis or tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: <b>[US Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with a known history of myasthenia gravis.</b> Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Syphilis: Since ciprofloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Theophylline: Serious and fatal reactions including seizures, status epilepticus, cardiac arrest, and respiratory failure have been reported with concomitant administration of theophylline. If concurrent use is unavoidable, monitor serum theophylline levels and adjust theophylline dose as warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric:  Adverse effects, including those related to joints and/or surrounding tissues, are increased in pediatric patients and therefore, ciprofloxacin should not be considered as drug of choice in children (exception is anthrax treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: <b>[US Boxed Warning]: Reserve use of ciprofloxacin for treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, or acute uncomplicated cystitis for patients who have no alternative treatment options because of the risk of disabling and potentially serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects).</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611328\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3, P-glycoprotein/ABCB1; <b>Inhibits</b> CYP1A2 (moderate), CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611329\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9053&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agomelatine: Ciprofloxacin (Systemic) may increase the serum concentration of Agomelatine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the arrhythmogenic effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the arrhythmogenic effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May increase the serum concentration of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bendamustine: Ciprofloxacin (Systemic) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Quinolones may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine: Ciprofloxacin (Systemic) may increase the serum concentration of Caffeine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents.<b> Exceptions: </b>Calcium Chloride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Ciprofloxacin (Systemic) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Ciprofloxacin (Systemic) may enhance the QTc-prolonging effect of CloZAPine. Ciprofloxacin (Systemic) may increase the serum concentration of CloZAPine.  Management: Reduce the clozapine dose to one-third of the original dose when adding ciprofloxacin and monitor closely for evidence of excessive QTc prolongation and clozapine toxicity.  Resume the previous clozapine dose following ciprofloxacin discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inhibitors): CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Ciprofloxacin (Systemic) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May enhance the QTc-prolonging effect of Ciprofloxacin (Systemic). Ciprofloxacin (Systemic) may diminish the therapeutic effect of Fosphenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: Quinolones may enhance the adverse/toxic effect of Heroin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: Ciprofloxacin (Systemic) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kola Nut: Ciprofloxacin (Systemic) may increase the serum concentration of Kola Nut. Specifically, ciprofloxacin may increase serum concentrations of caffeine, a major component of kola nut. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: Ciprofloxacin (Systemic) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meptazinol: May decrease the serum concentration of Ciprofloxacin (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Ciprofloxacin (Systemic) may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Ciprofloxacin (Systemic) may increase the serum concentration of Neratinib.  Management: Avoid concomitant use of neratinib and ciprofloxacin if possible. If combined, monitor for increased neratinib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: Ciprofloxacin (Systemic) may increase the serum concentration of Olaparib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patiromer: May decrease the serum concentration of Ciprofloxacin (Systemic). Management: Administer oral ciprofloxacin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: Ciprofloxacin (Systemic) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Ciprofloxacin (Systemic) may diminish the therapeutic effect of Phenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pirfenidone: Ciprofloxacin (Systemic) may increase the serum concentration of Pirfenidone.  Management: With ciprofloxacin doses of 1,500 mg/day, the pirfenidone dose should be reduced to 1,602 mg daily (ie, 534 mg three times a day). With lower daily doses of ciprofloxacin, use pirfenidone with caution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Ciprofloxacin (Systemic) may increase the serum concentration of Pomalidomide.  Management: Avoid concomitant use of pomalidomide and ciprofloxacin when possible. If coadministration is considered necessary, consider reducing the pomalidomide dose 50% and monitoring patients for increased pomalidomide effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Quinolones. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: Ciprofloxacin (Systemic) may increase the serum concentration of Roflumilast. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: Ciprofloxacin (Systemic) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ropivacaine: Ciprofloxacin (Systemic) may increase the serum concentration of Ropivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the absorption of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May enhance the arrhythmogenic effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Quinolones may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Ciprofloxacin (Systemic) may decrease the serum concentration of Thyroid Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: Ciprofloxacin (Systemic) may increase the serum concentration of TiZANidine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Quinolones may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: Ciprofloxacin (Systemic) may increase the serum concentration of Zolpidem.  Management: Consider avoiding the combination of ciprofloxacin and zolpidem if possible. If combined, monitor for signs of zolpidem toxicity (eg, somnolence, dizziness, lethargy).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611333\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases rate, but not extent, of absorption. Ciprofloxacin may increase serum caffeine levels if taken concurrently. Rarely, crystalluria may occur. Enteral feedings may decrease plasma concentrations of ciprofloxacin probably by &gt;30% inhibition of absorption. Management: May administer with most foods to minimize GI upset. If unable to avoid the following foods, administer ciprofloxacin at least 2 hours before or 6 hours after dairy products or calcium-fortified juices alone or in a meal containing &gt;800 mg calcium. Restrict caffeine intake if excessive cardiac or CNS stimulation occurs. Ensure adequate hydration during therapy. Ciprofloxacin should not be administered with enteral feedings. The feeding would need to be discontinued for 1 to 2 hours prior to and after ciprofloxacin administration. Nasogastric administration produces a greater loss of ciprofloxacin bioavailability than does nasoduodenal administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611259\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611260\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Ciprofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid and cord serum (Ludlam 1997). Based on available data, an increased risk of teratogenic effects has not been observed following ciprofloxacin use during pregnancy (Bar-Oz 2009; Padberg 2014). Ciprofloxacin is recommended for prophylaxis and treatment of pregnant women exposed to anthrax (Meaney-Delman 2014). Serum concentrations of ciprofloxacin may be lower during pregnancy than in nonpregnant patients (Giamarellou 1989). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611300\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of ciprofloxacin is 2.8% when calculated using the highest average breast milk concentration located and compared to an infant therapeutic dose of 20 mg/kg/day. In general, breastfeeding is considered acceptable when the relative infant dose is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest average milk concentration (3.79 mcg/mL), the estimated daily infant dose via breast milk is 0.569 mg/kg/day. This milk concentration was obtained following a maternal dose of ciprofloxacin 750 mg every 12 hours for 3 doses (n=10) (Giamarellou 1989).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There is a case report of perforated pseudomembranous colitis in a breastfeeding infant whose mother was taking ciprofloxacin (Harmon 1992). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin is recommended for the prophylaxis and treatment of <i>Bacillus anthracis</i> in breastfeeding women (Meaney-Delman 2014). Alternative agents are recommended in nursing women for the treatment of chancroid (CDC [Workowski 2015]). The manufacturer does not recommend use of ciprofloxacin in breastfeeding women due to concerns of potential articular damage; however, this risk is considered low even in children receiving high therapeutic doses. Therefore, some sources do not consider maternal use of ciprofloxacin to be a reason to discontinue nursing as long as the infant is monitored for gastrointestinal symptoms (eg, diarrhea) which could occur following antibiotic exposure (Kaplan 2015). Other sources recommend avoiding quinolone antibiotics if alternative agents are available (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611450\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: May be taken with meals that contain dairy products (eg, milk, yogurt) or calcium-fortified juices, but not with these products alone; separate administration of Cipro XR and calcium &gt;800 mg by at least 2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine: Patients consuming regular large quantities of caffeinated beverages may need to restrict caffeine intake if excessive cardiac or CNS stimulation occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611455\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, renal and hepatic function during prolonged therapy, altered mental status, signs and symptoms of tendonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611370\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611373\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well-absorbed; 500 mg orally every 12 hours produces an equivalent AUC to that produced by 400 mg IV over 60 minutes every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 2.1 to 2.7 L/kg; tissue concentrations often exceed serum concentrations especially in kidneys, gallbladder, liver, lungs, gynecological tissue, and prostatic tissue; CSF concentrations: 10% of serum concentrations (noninflamed meninges), 14% to 37% (inflamed meninges)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 20% to 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Partially hepatic; forms 4 metabolites (limited activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 50% to 85%; younger CF patients have a lower bioavailability of 68% vs CF patients &gt;13 years of age with bioavailability of 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children: 4 to 5 hours; Adults: Normal renal function: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Immediate release tablet: 0.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Extended release tablet: Cipro XR: 1 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (30% to 50% as unchanged drug); feces (15% to 43%; &lt;1% as unchanged drug)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Clearance: After IV: CF children: 0.84 L/hour/kg; Adults: 0.5 to 0.6 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611525\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cipro in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/200 mL (200 mL): $30.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ciprofloxacin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL (100 mL): $2.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/200 mL (200 mL): $3.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ciprofloxacin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $2.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/40 mL (40 mL): $4.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cipro Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 MG/5ML (5%) (100 mL): $149.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 MG/5ML (10%) (100 mL): $174.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Ciprofloxacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 MG/5ML (10%) (100 mL): $142.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Cipro XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $523.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (50): $595.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Ciprofloxacin-Ciproflox HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $489.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (50): $557.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cipro Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $588.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $688.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ciprofloxacin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (6): $91.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $443.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $530.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (50): $277.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961927\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AC Ear Drops (IN);</li>\n      <li>Acipro (PH);</li>\n      <li>Aciren (KR);</li>\n      <li>Adiflox (IN);</li>\n      <li>Alcon Cilox (CO, ID);</li>\n      <li>Antox (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Apoflox (MX);</li>\n      <li>Aprocin (HK);</li>\n      <li>Asflox (ET);</li>\n      <li>Bacquinor (ID);</li>\n      <li>Bactiflox (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Baflox (CO);</li>\n      <li>Baquinor (ID);</li>\n      <li>Baycip (CL, ES);</li>\n      <li>Bearcin (KR);</li>\n      <li>Bernoflox (ID);</li>\n      <li>C-Flox (AU, UY);</li>\n      <li>Cefaxin (KR);</li>\n      <li>Ceflox (IN);</li>\n      <li>Cetraxal (CR, DO, ES, GT, HN, NI, PA, SV);</li>\n      <li>Ciclodin (PH);</li>\n      <li>Cifex (PH);</li>\n      <li>Cifloc (ZA);</li>\n      <li>Ciflodal (PH);</li>\n      <li>Cifloptic (PE);</li>\n      <li>Ciflox (AE, FR, HR, KW, QA, VE);</li>\n      <li>Cifloxager (IE);</li>\n      <li>Cifloxin (HK, PH);</li>\n      <li>Cifox (IE);</li>\n      <li>Cifran (AU, BF, BJ, CI, CN, ET, GH, GM, GN, IN, KE, LK, LR, LV, MA, ML, MR, MU, MW, NE, NG, RO, SC, SD, SL, SN, TN, TZ, UG, VN, ZM, ZW);</li>\n      <li>Cilobact (CO);</li>\n      <li>Cilox (NO);</li>\n      <li>Cimoxin (PE);</li>\n      <li>Cinaflox (PE);</li>\n      <li>Cipflox (NZ);</li>\n      <li>Ciploc (PK);</li>\n      <li>Ciplox (BF, BJ, CI, ET, GH, GM, GN, HK, IE, KE, LR, LV, MA, ML, MR, MU, MW, NE, NG, SC, SD, SK, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Ciplus (KR);</li>\n      <li>Ciprecu (EC);</li>\n      <li>Ciprinol (BG, EE, LV, RO, SI);</li>\n      <li>Cipro (AR, BR, CO, JO, PY);</li>\n      <li>Cipro A (BD);</li>\n      <li>Cipro XR (BB, BM);</li>\n      <li>Cipro-Denk (TZ);</li>\n      <li>Ciprobac (MX);</li>\n      <li>Ciprobay (AE, BG, BH, CY, CZ, EG, IQ, IR, JO, KR, KW, LB, LY, MY, OM, PH, PL, QA, SA, SI, SY, TH, VN, YE, ZA, ZW);</li>\n      <li>Ciprobay Uro (DE);</li>\n      <li>Ciprobeta (DE);</li>\n      <li>Ciprobid (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TH, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Ciprobiotic (GT, HN, ID, NI);</li>\n      <li>Ciprocan (KR);</li>\n      <li>Ciprocep (TH);</li>\n      <li>Ciprocin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ciprodac (ZW);</li>\n      <li>Ciprodar (AE, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ciprodex (IL);</li>\n      <li>Ciproflox (CY, PE, SA);</li>\n      <li>Ciprogis (IL);</li>\n      <li>Ciproglen (MY);</li>\n      <li>Ciprol (AU);</li>\n      <li>Ciprolak (PE);</li>\n      <li>Ciprolet (SG);</li>\n      <li>Ciprolin (PE);</li>\n      <li>Ciprolon (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cipromed (PE);</li>\n      <li>Cipromycin (GR);</li>\n      <li>Cipropharm (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ciprophil (PH);</li>\n      <li>Ciprotal (PH);</li>\n      <li>Ciprouro SR (KR);</li>\n      <li>Ciproval (CL);</li>\n      <li>Ciprovar (ZW);</li>\n      <li>Ciprox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);</li>\n      <li>Ciproxan (JP);</li>\n      <li>Ciproxin (AT, AU, CH, DK, FI, GB, GR, HK, ID, IE, IT, KR, MT, NO, NZ, SE, TR, TW, ZW);</li>\n      <li>Ciproxina (BB, BM, BS, BZ, CR, CU, DO, EC, GT, HN, JM, MX, NI, NL, PA, PR, PT, SR, SV, TT);</li>\n      <li>Ciproxine (BE, LU);</li>\n      <li>Ciproxyl (HK, TH);</li>\n      <li>Cipzy (LK);</li>\n      <li>Ciriax (PE);</li>\n      <li>Cirok (PH, SG);</li>\n      <li>Ciroxin (TW);</li>\n      <li>Cirpobay (CN);</li>\n      <li>Citopcin (KR);</li>\n      <li>Cixa (TW);</li>\n      <li>Cobay (TH);</li>\n      <li>Cobay-500 (PH);</li>\n      <li>Cosflox (IN);</li>\n      <li>Cycin (KR, SG);</li>\n      <li>Cyplox (HK);</li>\n      <li>Cypral (VE);</li>\n      <li>Cypro (KR);</li>\n      <li>Dibactil (PY);</li>\n      <li>Eni (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Enoxin (SG, TH);</li>\n      <li>Eprocin (KR);</li>\n      <li>Estecina (ES);</li>\n      <li>Fexin (PH);</li>\n      <li>Flaproks (UA);</li>\n      <li>Floroxin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Floxabid (BD);</li>\n      <li>Floxager (MX);</li>\n      <li>Floxine (ET);</li>\n      <li>Floxsid (ID);</li>\n      <li>Glocip (VN);</li>\n      <li>Glojaya (ID);</li>\n      <li>Hexiquin (ID);</li>\n      <li>Hiflox (BD);</li>\n      <li>Hippro (TH);</li>\n      <li>Hippro Forte (TH);</li>\n      <li>Ifloxin (PH);</li>\n      <li>Interflox (ID);</li>\n      <li>Iprolan (PH);</li>\n      <li>Iprubac (PH);</li>\n      <li>Jayacin (ID);</li>\n      <li>Ladinin (ET);</li>\n      <li>Lofucin (KR);</li>\n      <li>Loxan (CO);</li>\n      <li>Maxpro (PH);</li>\n      <li>Medcoflox (ID);</li>\n      <li>Novaflox (SG);</li>\n      <li>Novidat (AR);</li>\n      <li>Oftacilox (PT);</li>\n      <li>Optal-Pro (TH);</li>\n      <li>Orlin (AE);</li>\n      <li>Orpic (PH);</li>\n      <li>Otosec (CO, PE);</li>\n      <li>Procip (NZ, ZW);</li>\n      <li>Proflox (EC, TH);</li>\n      <li>Profloxin (IE);</li>\n      <li>Proquin (AU);</li>\n      <li>Proxacin (BD, BR);</li>\n      <li>Pycip (MY);</li>\n      <li>Qilaflox (ID);</li>\n      <li>Qinosyn (PH);</li>\n      <li>Quilox (PH);</li>\n      <li>Quinobiotic (ID, PE);</li>\n      <li>Quinocip (LK);</li>\n      <li>Quinos (KR);</li>\n      <li>Quintor (ET);</li>\n      <li>Qupron (KR);</li>\n      <li>Sepcen (MT);</li>\n      <li>Serviflox (MY, SG);</li>\n      <li>Sifloks (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Siflox (ID);</li>\n      <li>Sophixin Ofteno (CR, DO, GT, HN, NI, PA, SV, VE);</li>\n      <li>Superocin (TW);</li>\n      <li>Supraflox (ET);</li>\n      <li>Tequinol (ID);</li>\n      <li>Topistin (SG);</li>\n      <li>Truoxin (IE);</li>\n      <li>Tsyprobay (UA);</li>\n      <li>Tsyprynol (UA);</li>\n      <li>Tyflox (ZW);</li>\n      <li>Unex (EC);</li>\n      <li>Uniflox (FR);</li>\n      <li>Uroxin (HK, SG);</li>\n      <li>Vexcipro (PH);</li>\n      <li>Viflox (ID);</li>\n      <li>Vistaflox (PH);</li>\n      <li>Xenoflox (PH);</li>\n      <li>Zindolin (TR);</li>\n      <li>Zumaflox (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agha R, Goldberg MB. Shigella infection: Treatment and prevention in adults. In: UpToDate, Post TE (ed). UpToDate. Waltham, MA (Accessed on June 22, 2017).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 66.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones--a meta-analysis of pregnancy outcomes. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2009;143(2):75-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19181435 /pubmed\" target=\"_blank\" id=\"19181435 \">19181435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span><span class=\"doi\">10.1093/cid/civ482</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26926640\"></a>Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to Escherichia coli: do rates vary by hospital characteristics and geographic region? <i>Antimicrob Agents Chemother</i>. 2016;60(5):3170-3173. doi: 10.1128/AAC.02505-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26926640/pubmed\" target=\"_blank\" id=\"26926640\">26926640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bossi P, Tegnell A, Baka A, et al; Taskforce on Bioterrorism (BICHAT), Public Health Directorate, European Commission, Luxembourg. BICHAT guidelines for the clinical management of tularemia and bioterrorism-related tularemia. <i>Euro Surveill</i>. 2004;9(12):E9-E10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15677845/pubmed\" target=\"_blank\" id=\"15677845\">15677845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011a, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. <i>Pediatrics</i>. 2011b;128(4):e1034-e1045.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21949152/pubmed\" target=\"_blank\" id=\"21949152\">21949152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-e1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24777226/pubmed\" target=\"_blank\" id=\"24777226\">24777226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calhoun JH, Manring MM. Adult osteomyelitis. <i>Infect Dis Clin North Am</i>. 2005;19(4):765-786.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16297731/pubmed\" target=\"_blank\" id=\"16297731\">16297731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Updated June 13, 2017. Accessed September 6, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Plague. Resources for Clinicians. <a href=\"http://www.cdc.gov/plague/healthcare/clinicians.html#treatment\" target=\"_blank\">http://www.cdc.gov/plague/healthcare/clinicians.html#treatment</a>. Updated October 5, 2015. Accessed June 9, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP), <i>MMWR Recomm Rep</i>, 2005, 54(RR-7):1-28. Available at <a href=\"http://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf\" target=\"_blank\">http://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo; <i>MMWR Recomm Rep</i>, 2007, 56(14):332-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/17431378/pubmed\" target=\"_blank\" id=\"17431378\">17431378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Recommendations for the use of antibiotics for the treatment of cholera: summary recommendations. 2015. Updated January 20, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, and Blumer JL, &ldquo;Antibiotics and Breast-Feeding: A Critical Review of the Literature,&rdquo; <i>Paediatr Drugs</i>, 2002, 4(12):817-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12431134/pubmed\" target=\"_blank\" id=\"12431134\">12431134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipro (ciprofloxacin) [product monograph]. Mississaugam Ontario, Canada: Bayer Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipro IV (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipro XL (ciprofloxacin) [product monograph]. Mississauga, Ontario, Canada; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipro XR (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ciprofloxacin injection [prescribing information]. North Brunswick, NJ: Claris Lifesciences; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26926407\"></a>Coker TJ, Dierfeldt DM. Acute Bacterial Prostatitis: Diagnosis and Management. <i>Am Fam Physician</i>. 2016;93(2):114-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26926407/pubmed\" target=\"_blank\" id=\"26926407\">26926407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Committee on Infectious Diseases, &ldquo;The Use of Systemic Fluoroquinolones,&rdquo; <i>Pediatrics</i>, 2006, 118(3):1287-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16951028/pubmed\" target=\"_blank\" id=\"16951028\">16951028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cover DL, Mueller BA. Ciprofloxacin penetration into human breast milk: a case report. <i>DICP</i>. 1990;24(7-8):703-704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2375140/pubmed\" target=\"_blank\" id=\"2375140\">2375140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies SP, Azadian BS, Kox WJ, et al, &ldquo;Pharmacokinetics of Ciprofloxacin and Vancomycin in Patients With Acute Renal Failure Treated by Continuous Haemodialysis,&rdquo; <i>Nephrol Dial Transplant</i>, 1992, 7(8):848-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1325620/pubmed\" target=\"_blank\" id=\"1325620\">1325620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de la Cabada Bauche J and DuPont HL. &ldquo;New Developments in Traveler&rsquo;s Diarrhea,&rdquo; <i>Gastroenterol Hepatol</i>, 2011, 7(2):88-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21475415/pubmed\" target=\"_blank\" id=\"21475415\">21475415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dennis DT, Inglesby TV, Henderson DA, et al; Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. <i>JAMA</i>. 2001;285(21):2763-2773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11386933/pubmed\" target=\"_blank\" id=\"11386933\">11386933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    File TM. Treatment of community-acquired pneumonia in adults in the outpatient setting. In: UpToDate. Post TE (ed). UpToDate. Waltham, MA (Accessed on June 22, 2017) [2017a].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    File TM. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. In: UpToDate. Post TE (ed), UpToDate, Waltham, MA (Accessed on June 22, 2017) [2017b].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2013;31(6):794-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23319691/pubmed\" target=\"_blank\" id=\"23319691\">23319691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA), &ldquo;CIPRO (Ciprofloxacin) Use by Pregnant and Lactating Women.&rdquo; Available at <a href=\"http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm\" target=\"_blank\">http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo; <i>Pharmacotherapy</i>, 2004, 24(12):1807-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15585448/pubmed\" target=\"_blank\" id=\"15585448\">15585448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gamboa F, Rivera JM, Gomez Mateos JM, et al, &ldquo;Ciprofloxacin-Induced Henoch-Sch&ouml;nlein Purpura,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(1):84.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardner DK, Gabbe SG, and Harter C, &quot;Simultaneous Concentrations of Ciprofloxacin in Breast Milk and in Serum in Mother and Breast-Fed Infant,&quot; <i>Clin Pharm</i>, 1992, 11(4):352-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1563233/pubmed\" target=\"_blank\" id=\"1563233\">1563233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giamarellou H, Kolokythas E, Petrikkos G, et al. Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women. Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida. <i>Am J Med</i>. 1989;87(5A):49S-51S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2589353 /pubmed\" target=\"_blank\" id=\"2589353 \">2589353 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldenberg DL, Sexton DJ. Septic arthritis in adults. In: UpToDate. Post TE (ed). UpToDate. Waltham, MA (Accessed on June 22, 2017).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guay DRP, Awni WM, Peterson PK, et al, &ldquo;Single and Multiple Dose Pharmacokinetics of Oral Ciprofloxacin in Elderly Patients,&rdquo; <i>Int J Clin Pharmacol Ther Toxicol</i>, 1988, 26(6):279-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/3410603/pubmed\" target=\"_blank\" id=\"3410603\">3410603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11170940\"></a>Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. <i>Clin Infect Dis.</i> 2001;32(3):331-351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11170940/pubmed\" target=\"_blank\" id=\"11170940\">11170940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21292654\"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/21292654/pubmed\" target=\"_blank\" id=\"21292654\">21292654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harmon T, Burkhart G, and Applebaum H, &quot;Perforated Pseudomembranous Colitis in the Breast-Fed Infant,&quot; <i>J Pediatr Surg</i>, 1992, 27(6):744-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1501036/pubmed\" target=\"_blank\" id=\"1501036\">1501036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26785402\"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med.</i> 2016;164(6):425-434. doi: 10.7326/M15-1840.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26785402/pubmed\" target=\"_blank\" id=\"26785402\">26785402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services (HHS). Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. 2013. Available at <a href=\"http://aidsinfo.nih.gov/guidelines\" target=\"_blank\">http://aidsinfo.nih.gov/guidelines</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24447897/pubmed\" target=\"_blank\" id=\"24447897\">24447897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hohmann EL. Nontyphoidal Salmonella: Gastrointestinal infection and carriage. In: UpToDate. Post TE (ed). UpToDate. Waltham, MA (Accessed on June 22, 2017).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1999905\"></a>Holley HP Jr. Successful treatment of cat-scratch disease with ciprofloxacin. <i>JAMA</i>. 1991;265(12):1563156-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1999905/pubmed\" target=\"_blank\" id=\"1999905\">1999905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hooton TM. Acute complicated cystitis and pyelonephritis. In: UpToDate. Post TE (ed). UpToDate. Waltham, MA (Accessed on June 22, 2017).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes WT, Armstrong D, Bodey GP, et al, &ldquo;2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer,&rdquo; <i>Clin Infect Dis</i>, 2002, 15;34(6):730-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11850858/pubmed\" target=\"_blank\" id=\"11850858\">11850858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inglesby TV, Dennis DT, Henderson DA, et al; Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. <i>JAMA</i>. 2000;283(17):2281-2290.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10807389/pubmed\" target=\"_blank\" id=\"10807389\">10807389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi:10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kapila K, Chysky V, Hullman R, et al, &ldquo;Worldwide Clinical Experience on Safety of Ciprofloxacin in Children on Compassionate Use Basis,&rdquo; <i>Proceedings of Third International Symposium on New Quinolones</i>, Vancouver, Canada, 1990, 9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan YC, Koren G. Use of ciprofloxacin during breastfeeding. <i>Can Fam Physician</i>. 2015;61(4):343-344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26052598/pubmed\" target=\"_blank\" id=\"26052598\">26052598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10423465\"></a>Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. <i>N Engl J Med</i>. 1999;341(5):312-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/10423465/pubmed\" target=\"_blank\" id=\"10423465\">10423465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo; <i>Clin Infect Dis</i>, 2003, 36(11):1404-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12766835/pubmed\" target=\"_blank\" id=\"12766835\">12766835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. <i>Lancet</i>. 1996;348(9023):296-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/8709688/pubmed\" target=\"_blank\" id=\"8709688\">8709688</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loebstein R, Addis A, Ho E, et al, &ldquo;Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study,&rdquo; <i>Antimicrob Agents Chemother</i>, 1998, 42(6):1336-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9624471/pubmed\" target=\"_blank\" id=\"9624471\">9624471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lomaestro BM and Bailie GR, &ldquo;Quinolone-Cation Interactions: A Review,&rdquo; <i>DICP</i>, 1991, 25(11):1249-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1763542/pubmed\" target=\"_blank\" id=\"1763542\">1763542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludlam H, Wreghitt TG, Thornton S, et al, &quot;Q Fever in Pregnancy,&quot; <i>J Infect</i>, 34(1):75-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9120330/pubmed\" target=\"_blank\" id=\"9120330\">9120330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mackay AD and Mehta A, &ldquo;Autoimmune Haemolytic Anemia Associated With Ciprofloxacin,&rdquo; <i>Clin Lab Haematol</i>, 1995, 17(1):97-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/7621639/pubmed\" target=\"_blank\" id=\"7621639\">7621639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo; <i>Antimicrob Agents Chemother</i>, 2001, 45(10):2949-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/11557500/pubmed\" target=\"_blank\" id=\"11557500\">11557500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17278083\"></a>Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society.Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44(suppl 2):S27-S72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014 Feb;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24457117 /pubmed\" target=\"_blank\" id=\"24457117 \">24457117 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyrier A, Fekete T. Acute bacterial prostatitis. In: UpToDate. Post TE (ed). UpToDate. Waltham, MA (Accessed on June 22, 2017) [2017a].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyrier A, Fekete T. Chronic bacterial prostatitis. In: UpToDate. Post TE (ed). UpToDate. Waltham, MA (Accessed on June 22, 2017) [2017b].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(10):1303-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16185173/pubmed\" target=\"_blank\" id=\"16185173\">16185173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mullen CA, &ldquo;Ciprofloxacin in Treatment of Fever and Neutropenia in Pediatric Cancer Patients,&rdquo;<i>Pediatr Infect Dis J</i>, 2003, 22(12):1138-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/14688588/pubmed\" target=\"_blank\" id=\"14688588\">14688588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson-Ehle I and Ljungberg B, &ldquo;Quinolone Disposition in the Elderly: Practical Implications,&rdquo; <i>Drugs Aging</i>, 1991, 1(4):279-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/1794020/pubmed\" target=\"_blank\" id=\"1794020\">1794020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nix DE, Cumbo TJ, Kuritzky P, DeVito JM, Schentag JJ. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. <i>Am J Med</i>. 1987;82(4A):146-153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/3555029/pubmed\" target=\"_blank\" id=\"3555029\">3555029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24841264 /pubmed\" target=\"_blank\" id=\"24841264 \">24841264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paul J and Brown NM, &ldquo;Tinnitus and Ciprofloxacin,&rdquo; <i>BMJ</i>, 1995, 311(6999):232.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. <i>Am J Med</i>. 1989;86(6 Pt 2):801-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/2658581/pubmed\" target=\"_blank\" id=\"2658581\">2658581</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rfidah EI, Findlay CA, and Beattie TJ, &ldquo;Reversible Encephalopathy After Intravenous Ciprofloxacin Therapy,&rdquo; <i>Pediatr Nephrol</i>, 1995, 9(2):250-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/7794728/pubmed\" target=\"_blank\" id=\"7794728\">7794728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers&rsquo; diarrhea: a graded expert panel report. <i>J Travel Med.</i> 2017;24(suppl 1):S57-S74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28521004/pubmed\" target=\"_blank\" id=\"28521004\">28521004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi: 10.1038/ajg.2016.126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/27068718/pubmed\" target=\"_blank\" id=\"27068718\">27068718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. <i>Hepatology</i>. 1995;22(4, pt 1):1171-1174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/7557868 /pubmed\" target=\"_blank\" id=\"7557868 \">7557868 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25833927\"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis executive summary. <i>Otolaryngol Head Neck Surg</i>. 2015;152(4):598-609. doi: 10.1177/0194599815574247.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/25833927/pubmed\" target=\"_blank\" id=\"25833927\">25833927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubio TT, Miles MV, Lettieri JT, et al, &ldquo;Pharmacokinetic Disposition of Sequential Intravenous/Oral Ciprofloxacin in Pediatric Cystic Fibrosis Patients With Acute Pulmonary Exacerbation,&rdquo; <i>Pediatr Infect Dis J</i>, 1997, 16:112-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/9002120/pubmed\" target=\"_blank\" id=\"9002120\">9002120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Alexandria, VA: American Association for the Study of Liver Diseases; 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 12, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA. Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis. In: UpToDate. Post TE (ed). UpToDate. Waltham, MA (Accessed on July 24, 2017).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryan ET, Andrew J. Treatment and prevention of typhoid fever. In: UpToDate. Post TE (ed). UpToDate. Waltham, MA (Accessed on June 22, 2017).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16760445\"></a>Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. <i>N Engl J Med</i>. 2006;354(23):2452-2462.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16760445/pubmed\" target=\"_blank\" id=\"16760445\">16760445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaad UB, abdus Salam M, Aujard Y, et al, &ldquo;Use of Fluoroquinolones in Pediatrics: Consensus Report of an International Society of Chemotherapy Commission,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(1):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/7715981/pubmed\" target=\"_blank\" id=\"7715981\">7715981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sedlak T, Shufelt C, Iribarren C, et al, &quot;Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval,&quot; <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/23879279/pubmed\" target=\"_blank\" id=\"23879279\">23879279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. <i>Clin Infect Dis. </i>2017;65(12):e45-e80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/29053792/pubmed\" target=\"_blank\" id=\"29053792\">29053792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Spach.2017\"></a>Spach DH, Kaplan SL. Treatment of catch scratch disease. In: UpToDate, Post TW (ed). UpToDate. Waltham, MA. Accessed on June 22, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24973422\"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo; <i>N Engl J Med</i>, 1995, 332(3):193.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28360365\"></a>Szeto CC, Li PK<sup>2</sup>, Johnson DW, et al. ISPD Catheter-Related Infection Recommendations: 2017 Update. <i>Perit Dial Int</i>. 2017 Mar-Apr;37(2):141-154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28360365/pubmed\" target=\"_blank\" id=\"28360365\">28360365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. <i>J Hepatol</i>. 2008;48(5):774-779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/18316137 /pubmed\" target=\"_blank\" id=\"18316137 \">18316137 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Disease Society of America&rsquo;s Clinical Practice Guidelines for Healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/28203777/pubmed\" target=\"_blank\" id=\"28203777\">28203777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12685882\"></a>Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. <i>Scand J Infect Dis</i>. 2003;35(1):34-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12685882/pubmed\" target=\"_blank\" id=\"12685882\">12685882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32 (suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. In: UpToDate, Post TE (ed). UpToDate. Waltham, MA. Accessed on June 22, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wingard RJ. Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults. In: UpToDate, Post TE (ed). UpToDate. Waltham, MA. Accessed on June 22, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &ldquo;Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae type 1&rdquo;, 2005. Available at http://whqlibdoc.who.int/publications/2005/9241592330.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoon BI, Han DS, Ha US, et al. Clinical courses following acute bacterial prostatitis. <i>Prostate Int</i>. 2013;1(2):89-93. doi: 10.12954/PI.12013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/24223408/pubmed\" target=\"_blank\" id=\"24223408\">24223408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo; <i>Ann Pharmacother</i>, 2004, 38:1525-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/15252190/pubmed\" target=\"_blank\" id=\"15252190\">15252190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group, &ldquo;Multicenter, Randomized, Double Blind Clinical Trial of Short Course Versus Standard Course Oral Ciprofloxacin for <i>Shigella dysenteriae</i> Type 1 Dysentery in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 2002, 21(12):1136-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-drug-information/abstract-text/12488664/pubmed\" target=\"_blank\" id=\"12488664\">12488664</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9053 Version 291.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9611220\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9611233\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9611234\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9660646\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9611424\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9611423\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9611425\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9611426\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22902778\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9611523\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9611236\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9611231\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9611451\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9611256\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475322\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3198418\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9611304\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9611301\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9611302\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9611328\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9611329\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F9611333\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9611259\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9611260\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9611300\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9611450\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9611455\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9611370\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9611373\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9611525\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961927\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9053|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ciprofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">Ciprofloxacin (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=ciprofloxacin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Ciprofloxacin (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}